ProCE Banner Activity

CE / CME

Distinguishing Tardive Dyskinesia From Other Drug-Induced Movement Disorders

Video

Watch this on-demand webcast of a live CCO presentation on distinguishing tardive dyskinesia from drug-induced parkinsonism and why it is important to treat sooner rather than later.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Released: October 26, 2022

Expiration: October 25, 2023

No longer available for credit.

Share

Faculty

Stuart Isaacson

Stuart Isaacson, MD

Clinical Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Miami, Florida
Director
Parkinsons Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Teva

Target Audience

This program is intended for a multidisciplinary audience of neurologists, psychiatrists, primary care physicians, nurses, physician assistants/physician associates, pharmacists, and other members of the healthcare team involved in the management of patients with neurological and movement disorders.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate characteristics of drug-induced movement disorders that can assist with accurate diagnosis
  • Compare and contrast treatment of different drug-induced movement disorders
  • Assess the safety and efficacy of VMAT2 inhibitors for tardive dyskinesia

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Stuart Isaacson, MD

Clinical Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Miami, Florida
Director
Parkinsons Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida

Stuart Isaacson, MD: consultant/advisor/speaker: Neurocrine, Supernus, Teva.

Staff Disclosure

Staff

Raquel Gaerlan,

Director, Scientific Services

Raquel Gaerlan has no relevant financial relationships to disclose.

Gabrielle Giacona,

Associate Scientific Director

Gabrielle Giacona: individual publicly traded stocks/stock options: AstraZeneca, Moderna, Teva.

Jessie Gibson, PHD, RN, AGPCNP-BC

Jessie Gibson, PhD, RN, AGPCNP-BC: advisor/consultant/speaker: Teva.

Amber Lemons, PharmD, BCPP

Director, Educational Strategy

Amber Lemons, PharmD, BCPP, has no relevant financial relationships to disclose.

Leslie Matson, MPA, PA-C

Leslie Matson, MPA, PA-C, has no relevant financial relationships to disclose.

Lisa Phipps, PharmD, PhD

Director, Science and Strategy, Neuroscience

Lisa Phipps, PharmD, PhD, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-265-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant/Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for maximum of 1.0 AAPA Category 1 CME credit. Approval is valid until October 25, 2023. PAs should only claim commensurate with the extent of their participation.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 26, 2022, through October 25, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve the knowledge, competence, and performance of learners to assess diagnostic considerations and new and emerging therapies for the treatment of neurological and movement disorders.